Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Connect Biopharma Holdings Limited
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
connect.orgAI Executive Summary
AI-powered analysis of 8-K filing content
Connect Biopharma announced topline results from a global phase 2 study of rademikibart, a next-generation anti-IL-4 receptor alpha antibody for COPD with type 2 inflammation, representing a significant advancement in the company's product pipeline and potential future revenue opportunity.
Key Takeaways
Rademikibart demonstrated clinical potential as an add-on treatment for acute exacerbations in COPD patients with type 2 inflammation
Phase 2 study results support progression toward potential commercialization and market entry
2 more takeaways
Filing Overview
What This Means
Connect Biopharma Holdings Limited filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.